# First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)

> **NCT04483297** · PHASE1 · TERMINATED · sponsor: **Asahi Kasei Therapeutics Corporation** · enrollment: 30 (actual)

## Conditions studied

- Degenerative Spondylolisthesis
- Spinal Stenosis

## Interventions

- **DRUG:** AK1320 MS
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT04483297
- **Lead sponsor:** Asahi Kasei Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-18
- **Primary completion:** 2023-11-27
- **Final completion:** 2024-01-30
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483297, "First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04483297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*